Production and computational fluid dynamics-based modeling of PMMA nanoparticles impregnated with ivermectin by a supercritical antisolvent process

Valarini, Osvaldo; Cardoso, Flávia Aparecida Reitz; Giufrida, Willyan Machado; Souza, Marilesia Ferreira de; Cardozo‐Filho, Lúcio

doi:10.1016/j.jcou.2019.08.025

Cited by 16 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PMMA (average MW = 120 000 g mol −1 ) and a dialysis membrane (cutoff 12 000) were acquired from Sigma‐Aldrich (Brazil); Purex egg lecithin was purchased from FR Lab (Brazil); CO 2 (99.9% purity) was obtained from White Martins (Brazil); DCM (99.9% purity) was acquired from SP Labor (Brazil); ethanol (99.9% purity) was obtained from Anidrol (Brazil), and IVM (C 48 H 74 O 14 , 97.5% purity, MW = 875.1 g mol −1 , CAS number 71827‐03‐7) was acquired from Hebei Veyong Animal Pharmaceutical (China) 20 …”

Section: Methodsmentioning

confidence: 99%

“…The production of lecithin/PMMA NPs formulated with IVM was performed in the Super Particle SAS Model 200 (Thar SFC, USA) equipment (Figure 1) according to our previous study 20 . A 30 mg of polymer (PMMA) per milliliter of solvent (DCM) and 10% of the drug in relation to the polymer by weight was used 12,20 . Different lecithin concentrations, varying from 10% to 30% in relation to the polymer (PMMA) were evaluated.…”

Section: Methodsmentioning

confidence: 99%

“…After the solution injection, the solid NPs produced due to the antisolvent effect of the CO 2 were collected on a sintered filter at the bottom of the vessel. Drying and purification processes were carried out with pure CO 2 under the same operating conditions for 30 min 20 . The stainless‐steel cylinder‐shaped expansion vessel (5) has an approximate volume of 2 L. The temperature and pressure control of the vessel was performed using a heat exchanger (4) and an automatic back pressure regulator valve (6) (model ABPR, Thar SFC, USA) respectively.…”

Section: Methodsmentioning

confidence: 99%

“…The stainless‐steel cylinder‐shaped expansion vessel (5) has an approximate volume of 2 L. The temperature and pressure control of the vessel was performed using a heat exchanger (4) and an automatic back pressure regulator valve (6) (model ABPR, Thar SFC, USA) respectively. The organic solvent used in the study was separated from the CO 2 and recovered in a second 500‐ml stainless steel chamber (8) at a pressure of 1.7 MPa 20 …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Single step encapsulation process of ivermectin in biocompatible polymer using a supercritical antisolvent system process

Valarini

Cardoso

Souza

et al. 2021

Asia-Pacific J Chem Eng

Self Cite

View full text Add to dashboard Cite

This paper reports the production of ivermectin (IVM)‐encapsulated lecithin/poly (methyl methacrylate) (PMMA) nanoparticles via supercritical antisolvent system (SAS). Of a total of nine formulations, experimental condition R7 containing 10% lecithin relative to polymer (PMMA) resulted in the smallest average experimental particle diameter (dexp), more stable surface charges and high IVM encapsulation efficiency (75.9 ± 2.5%). Nanoparticles were morphologically, thermally, and conformationally characterized using scanning electron microscopy (SEM), thermogravimetric analysis/thermogravimetric derivative (TGA/DTG), and Fourier transform infrared–attenuated total reflectance (FTIR/ATR) techniques. In vitro release test showed that the drug has a controlled release of approximately 110 h. Peppas–Sahlin model (R2 = 0.99) was able to describe the diffusion of the drug correctly. Cytotoxicity analysis showed high compatibility of nanoparticles with epithelial cells, fibroblasts, and macrophages. Population balance equation was used to determine kinetic parameters from experimental data of average particle diameter. Synthesized nanoparticles showed high solution stability, good encapsulation capacity, and showed no adverse effects on cell viability, indicating their high potential as a new IVM carrier system for veterinary medicine and human applications.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Single step encapsulation process of ivermectin in biocompatible polymer using a supercritical antisolvent system process

Valarini

Cardoso

Souza

et al. 2021

Asia-Pacific J Chem Eng

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinicamente, a IVM foi aprovada como medicamento antiparasitário de amplo espectro (contra endoparasitas e ectoparasitas) para uso em humanos, no tratamento de doenças tropicais de infecções parasitárias como sarna, piolhos, tricuríase, oncocercose, filariose linfática e estrongiloidíase, e veterinário, para prevenir e tratar a filariose causadas por Dirofilaria immitis e Rhipicephaluslu microplus (McCall et al, 2005;Genchi et al, 2009 ;Das et al, 2020). O principal mecanismo de ação do fármaco envolve a ativação dos canais de cloreto, mediados por glutamato ou pelo ácido gama-aminobutírico (GABA), permitindo o influxo de íons cloreto que causam a paralisia da musculatura e morte do parasita (Õmura, 2008;Valarini Jr, et al 2020).…”

Section: Introductionunclassified

Ivermectina: é preciso pensar fora da caixa para reposicioná-la

Ramalho

Sousa

Gomes

et al. 2020

RSD

View full text Add to dashboard Cite

A ivermectina (IVM) é um fármaco derivado da avermectina B1 de alta permeabilidade e baixa solubilidade. É utilizado como antiparasitário de amplo espectro e estudos revelam promissoras atividades antiviral e anti-inflamatória. Além disso, formulações e sistemas de liberação têm sido aplicados para otimizar a solubilidade e biodisponibilidade do fármaco. Desse modo, pretende-se destacar o desenvolvimento de novas formulações e sistemas de liberação contendo a IVM tendo em vista não só os benefícios tecnológicos, mas também os proveitos de efetividade diante de distúrbios distintos para os quais o fármaco não foi originalmente aplicado. Os sistemas de liberação têm sido aplicados para otimizar a solubilidade e biodisponibilidade da IVM, reduzir sua citotoxicidade e aumentar o efeito terapêutico em doses menores. Nesse sentido, a literatura revela distintas formulações e sistemas de liberação contendo IVM que visam melhorar suas propriedades físico-químicas, tais como micropartículas, microesferas, lipossomas, microemulsões, gel de formação in situ, formulações de liberação controlada e prolongada, dispersão sólida e micelas mistas. Como potencial agente antiviral, este fármaco inibe a replicação de cepas virais e reduz níveis séricos de proteína viral em estudos in vitro e in vivo; quando incorporada em lipossomas, a eficácia foi elevada e toxicidade reduzida. A IVM demonstrou potencial para aplicação em distúrbios dermatológicos devido a atividade anti-inflamatória, destacando o reposicionamento bem sucedido para o tratamento de rosácea papulopustular. Portanto, reposicionar fármacos mais antigos para tratar doenças comuns ou raras, bem como diante de uma urgente necessidade, torna-se uma ferramenta atraente no âmbito da pesquisa e desenvolvimento de medicamentos.

show abstract

Kinetic Modeling to Explain the Release of Medicine from Drug Delivery Systems

Askarizadeh,

Esfandiari,

Honarvar

et al. 2023

ChemBioEng Reviews

View full text Add to dashboard Cite

Proper medication dissolution must be ensured when developing or manufacturing a new solid dosage form. Quantitative analyses performed in dissolution or release tests become simpler when applying mathematical formulae which represent dissolution outcomes as a function of several dosage form properties. Methodologies utilized to examine the kinetics of drug release from controlled‐release formulations are reviewed. The analysis of variance was conducted using statistical, model‐independent, and ‐dependent techniques for the dissolution profile comparison and fitting, respectively. Model equations, including zero‐ and first‐order, Hixson‐Crowell, Weibull, Higuchi, Korsmeyer‐Peppas, Baker‐Lonsdale, Hopfenberg, etc., were employed to match the experimental data. Additional release parameters were taken to illustrate the drug release patterns. Using correlation factors and the Akaike information criterion (AIC), the best‐fitting model was discovered, as were the transport phenomena affecting the behavior of the recognized formulations.

show abstract

Production and computational fluid dynamics-based modeling of PMMA nanoparticles impregnated with ivermectin by a supercritical antisolvent process

Cited by 16 publications

References 48 publications

Single step encapsulation process of ivermectin in biocompatible polymer using a supercritical antisolvent system process

Single step encapsulation process of ivermectin in biocompatible polymer using a supercritical antisolvent system process

Ivermectina: é preciso pensar fora da caixa para reposicioná-la

Kinetic Modeling to Explain the Release of Medicine from Drug Delivery Systems

Contact Info

Product

Resources

About